[Video Profile] Interview with Harry Stylli, President & CEO of Sequenom

Sequenom’s MassARRAY system is a DNA analysis platform that measures the amount of genetic target material and variations therein. MassARRAY delivers reliable and specific data from biological samples and from genetic target material that is only available in trace amounts.

With MassARRAY, Sequenom is commercializing non-invasive prenatal genetic tests. The company seeks to bring to market, safe, non-invasive prenatal testing for all women, regardless of age, or other factors, that may contribute to pregnancy complications.

For years doctors have used tests such as amniocentesis or chorionic villus to determine the health of a fetus. The introduction of Sequenom’s Fetal Nucleic Acid Technology is a potential alternative to these common procedures. Sequenom technology is non-invasive, thereby posing no risk to the baby, and has the potential to be performed earlier in the pregnancy.

The company’s SEQureDx technology isolates and analyzes circulating fetal nucleic acid from a maternal blood sample. The technology has particular promise for developing new, non-invasive tests for fetal gene and chromosome abnormalities such as RhD, fetal sex determination and Trisomy – including trisomy 21. The first test using SEQureDx technology, fetal RhD, became available in 2007.

The comments are closed.